179 related articles for article (PubMed ID: 9144006)
21. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons.
Hosaka N; Oyaizu N; Kaplan MH; Yagita H; Pahwa S
J Infect Dis; 1998 Oct; 178(4):1030-9. PubMed ID: 9806031
[TBL] [Abstract][Full Text] [Related]
22. Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis.
Tendler CL; Greenberg SJ; Burton JD; Danielpour D; Kim SJ; Blattner WA; Manns A; Waldmann TA
J Cell Biochem; 1991 Aug; 46(4):302-11. PubMed ID: 1757474
[TBL] [Abstract][Full Text] [Related]
23. VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease.
Silvestris F; Cafforio P; Tucci M; Del Prete A; Dammacco F
Mol Med; 2000 Jun; 6(6):509-26. PubMed ID: 10972087
[TBL] [Abstract][Full Text] [Related]
24. Soluble Fas (APO-1/CD95) isoform in adult T-cell leukemia.
Kamihira S; Yamada Y
Leuk Lymphoma; 2001 Mar; 41(1-2):169-76. PubMed ID: 11342370
[TBL] [Abstract][Full Text] [Related]
25. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure.
Adamopoulos S; Parissis J; Karatzas D; Kroupis C; Georgiadis M; Karavolias G; Paraskevaidis J; Koniavitou K; Coats AJ; Kremastinos DT
J Am Coll Cardiol; 2002 Feb; 39(4):653-63. PubMed ID: 11849865
[TBL] [Abstract][Full Text] [Related]
26. Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery.
Kawahito K; Misawa Y; Fuse K
Artif Organs; 2000 Aug; 24(8):628-31. PubMed ID: 10971250
[TBL] [Abstract][Full Text] [Related]
27. Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
Yamada Y; Endo S; Nakae H; Makabe H; Sato N; Wakabayashi G; Kitamura M; Inada K; Sato S
Burns; 2003 Dec; 29(8):799-802. PubMed ID: 14636754
[TBL] [Abstract][Full Text] [Related]
28. Modulatory effects of curcumin on apoptosis and cytotoxicity-related molecules in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients.
Mohammadi A; Fazeli B; Taheri M; Sahebkar A; Poursina Z; Vakili V; Yazdi SZ; Keramati Z; Boostani R; Hampson I; Rafatpanah H
Biomed Pharmacother; 2017 Jan; 85():457-462. PubMed ID: 27894665
[TBL] [Abstract][Full Text] [Related]
29. Dysregulation of apoptosis in scorpion envenomed children: its reflection on their outcome.
Meki AR; Hasan HA; El-Deen ZM; Bakkar S
Toxicon; 2003 Sep; 42(3):229-37. PubMed ID: 14559073
[TBL] [Abstract][Full Text] [Related]
30. Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients.
Lapinski TW; Kowalczuk O; Prokopowicz D; Chyczewski L
World J Gastroenterol; 2004 Dec; 10(24):3650-3. PubMed ID: 15534924
[TBL] [Abstract][Full Text] [Related]
31. Soluble Fas in the serum of patients with non-Hodgkin's lymphoma: higher concentrations in angioimmunoblastic T-cell lymphoma.
Yufu Y; Choi I; Hirase N; Tokoro A; Noguchi Y; Goto T; Uike N; Kozuru M
Am J Hematol; 1998 Aug; 58(4):334-6. PubMed ID: 9692400
[TBL] [Abstract][Full Text] [Related]
32. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers.
Araki K; Harada K; Nakamoto K; Shiroma M; Miyakuni T
Clin Exp Immunol; 2000 Feb; 119(2):259-63. PubMed ID: 10632660
[TBL] [Abstract][Full Text] [Related]
34. A Fas
Menezes SM; Leal FE; Dierckx T; Khouri R; Decanine D; Silva-Santos G; Schnitman SV; Kruschewsky R; López G; Alvarez C; Talledo M; Gotuzzo E; Nixon DF; Vercauteren J; Brassat D; Liblau R; Vandamme AM; Galvão-Castro B; Van Weyenbergh J
Front Immunol; 2017; 8():97. PubMed ID: 28261198
[TBL] [Abstract][Full Text] [Related]
35. CSF soluble Fas correlates with the severity of HIV-associated dementia.
Towfighi A; Skolasky RL; St Hillaire C; Conant K; McArthur JC
Neurology; 2004 Feb; 62(4):654-6. PubMed ID: 14981191
[TBL] [Abstract][Full Text] [Related]
36. Elevation of soluble Fas and soluble Fas ligand in reactive macrophage activation syndromes.
Emmenegger U; Zehnder R; Frey U; Reimers A; Spaeth PJ; Neftel KA
Am J Hematol; 2000 Jun; 64(2):116-9. PubMed ID: 10814991
[TBL] [Abstract][Full Text] [Related]
37. Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy.
Inoue A; Koh CS; Sakai T; Yamazaki M; Yanagisawa N; Usuku K; Osame M
J Neuroimmunol; 1997 May; 75(1-2):141-6. PubMed ID: 9143247
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system.
Wang XZ; Chen XC; Chen YX; Zhang LJ; Li D; Chen FL; Chen ZX; Chen HY; Tao QM
World J Gastroenterol; 2003 Dec; 9(12):2671-5. PubMed ID: 14669310
[TBL] [Abstract][Full Text] [Related]
39. Plasma sFas and sFas ligand levels in patients with thrombotic thrombocytopenic purpura and in those with disseminated intravascular coagulation.
Hori Y; Wada H; Mori Y; Shimura M; Hiyoyama K; Nakasaki T; Nishii K; Tamaki S; Nishikawa M; Deguchi K; Minami N; Shiku H
Am J Hematol; 1999 May; 61(1):21-5. PubMed ID: 10331507
[TBL] [Abstract][Full Text] [Related]
40. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis.
Sugita S; Taguchi C; Takase H; Sagawa K; Sueda J; Fukushi K; Hikita N; Watanabe T; Itoh K; Mochizuki M
Br J Ophthalmol; 2000 Oct; 84(10):1130-4. PubMed ID: 11004098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
